Back to Search Start Over

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.

Authors :
Frank D
Patnana PK
Vorwerk J
Mao L
Gopal LM
Jung N
Hennig T
Ruhnke L
Frenz JM
Kuppusamy M
Autry R
Wei L
Sun K
Mohammed Ahmed HM
Künstner A
Busch H
Müller H
Hutter S
Hoermann G
Liu L
Xie X
Al-Matary Y
Nimmagadda SC
Cano FC
Heuser M
Thol F
Göhring G
Steinemann D
Thomale J
Leitner T
Fischer A
Rad R
Röllig C
Altmann H
Kunadt D
Berdel WE
Hüve J
Neumann F
Klingauf J
Calderon V
Opalka B
Dührsen U
Rosenbauer F
Dugas M
Varghese J
Reinhardt HC
von Bubnoff N
Möröy T
Lenz G
Batcha AMN
Giorgi M
Selvam M
Wang E
McWeeney SK
Tyner JW
Stölzel F
Mann M
Jayavelu AK
Khandanpour C
Source :
Blood [Blood] 2023 Dec 21; Vol. 142 (25), pp. 2175-2191.
Publication Year :
2023

Abstract

Abstract: Growth factor independence 1 (GFI1) is a DNA-binding transcription factor and a key regulator of hematopoiesis. GFI1-36N is a germ line variant, causing a change of serine (S) to asparagine (N) at position 36. We previously reported that the GFI1-36N allele has a prevalence of 10% to 15% among patients with acute myeloid leukemia (AML) and 5% to 7% among healthy Caucasians and promotes the development of this disease. Using a multiomics approach, we show here that GFI1-36N expression is associated with increased frequencies of chromosomal aberrations, mutational burden, and mutational signatures in both murine and human AML and impedes homologous recombination (HR)-directed DNA repair in leukemic cells. GFI1-36N exhibits impaired binding to N-Myc downstream-regulated gene 1 (Ndrg1) regulatory elements, causing decreased NDRG1 levels, which leads to a reduction of O6-methylguanine-DNA-methyltransferase (MGMT) expression levels, as illustrated by both transcriptome and proteome analyses. Targeting MGMT via temozolomide, a DNA alkylating drug, and HR via olaparib, a poly-ADP ribose polymerase 1 inhibitor, caused synthetic lethality in human and murine AML samples expressing GFI1-36N, whereas the effects were insignificant in nonmalignant GFI1-36S or GFI1-36N cells. In addition, mice that received transplantation with GFI1-36N leukemic cells treated with a combination of temozolomide and olaparib had significantly longer AML-free survival than mice that received transplantation with GFI1-36S leukemic cells. This suggests that reduced MGMT expression leaves GFI1-36N leukemic cells particularly vulnerable to DNA damage initiating chemotherapeutics. Our data provide critical insights into novel options to treat patients with AML carrying the GFI1-36N variant.<br /> (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Details

Language :
English
ISSN :
1528-0020
Volume :
142
Issue :
25
Database :
MEDLINE
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
37756525
Full Text :
https://doi.org/10.1182/blood.2022015752